Clinical Trials
Our patients have the opportunity to participate in a wide variety of clinical trials of novel therapies, including both drug and adjunctive treatments. We also conduct studies that test biomarkers and diagnostic tests. Many of our faculty are also active in trial development and design. A large focus has been on vasculitis and scleroderma trials to date, with an expansion to other disease areas now including gout and osteoarthritis. Recent examples of trials in scleroderma have included agents to treat pulmonary hypertension, digital ulcers, lung disease, skin fibrosis and overall disease therapy. Our program is an active member of the Scleroderma Clinical Trials Consortium (SCTC), an international group that conducts multicenter trials of therapies in scleroderma. We are also actively enrolling interested patients in a variety of ongoing studies to assess clinical and biologic outcomes in a variety of rheumatic diseases.
Our programs also serve as important educational hub for other physicians and trainees to enhance awareness and clinical care in rheumatic diseases.
Active trials change frequently, so please contact us directly for questions about enrolling trials.
Clinical Trials Actively Recruiting
Systemic Sclerosis Study
-
- Purpose: The Study seeks to evaluate the Efficacy and Safety of PRA023 in subjects with Systemic Sclerosis associated with Interstitial Lung Disease
- Eligibility: Subjects must have had Systemic Sclerosis onset for 5 years or greater
- Time Commitment: 15 study visits over 50 week time frame
- Study Location: Boston University Medical Center
- Honorarium: $75 per completed visit
Diffuse Cutaneous Systemic Sclerosis Study
-
- Purpose: The overall objective is to investigate the efficacy, safety and tolerability of 2 dose regimens of HZN-825 in the treatment of subjects with diffuse cutaneous systemic sclerosis
- Eligibility: Male or female between the ages of 18 and 75 years and less than 36 months since the onset of the first SSc manifestation
- Time Commitment: 12 study visits over 52 week time frame
- Study Location: Boston University Medical Center
- Honorarium: $58 per completed visit
Topaz- 2 Study (Lupus)
- Purpose: The main objective is to evaluate the efficacy and safety of BIIB059 in adult participants with active systemic lupus erythematosus (SLE) who are receiving background nonbiologic lupus standard of care
- Eligibility: Subjects must be 18 years old or more with active SLE and stable background nonbiologic lupus standard of care therapy
- Time Commitment: 22 study visits over a period of about 1 year
- Study Location: General Clinical Research Unit (GCRU) at Boston University School of Medicine
- Honorarium: $77 per completed study visit
InflammOA- Knee Osteoarthritis Study
- Purpose: The overall objective is to evaluate the safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis (OA) , and to determine the efficacy of DFV890 in reducing knee pain as evidenced by change in Knee Injury and Osteoarthritis Outcome Score (KOOS).
- Eligibility: 50-80 year old adults with symptomatic knee osteoarthritis and BMI within the range of 18-35 kg/ m2
- Time Commitment: 9 study visits over a period of about 6 months.
- Study Location: General Clinical Research Unit (GCRU) at Boston University Chobanian and Avedisian School of Medicine.
- Honorarium: $160 per completed study visit.
Interested in taking part in a Clinical Trial?
Do you suffer from any of the following conditions?
Scleroderma |
Lupus
|
Inflammatory Arthritis |
Rheumatoid Arthritis
|
Gout
|
Spondyloarthritis
|
Psoriatic Arthritis
|
Ankylosing Spondylitis
|
Osteoarthritis
|
Myositis
|
Vasculitis
|
|
By completing the below form, you are agreeing to have the Clinical Trials Coordinator contact you. Your personal information will not be shared with anyone.
Contact Us